New antiplatelet and anticoagulant drugs.
Department of Oral Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, USA.
Richard L
RL
Wynn
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D017742:Dental Care for Chronically Ill; D065427:Factor Xa Inhibitors; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use; D006472:Oral Hemorrhage / Q000517:prevention & control; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D000068799:Prasugrel Hydrochloride; D000069604:Dabigatran